ライフサイエンスコーパス: fibroid

1 tive age are affected by uterine leiomyomas (fibroids).

2 Of 5,023 participants, 11% had a fibroid.

3 enriched according to the size of a uterine fibroid.

4 vessels with decreased diameters within the fibroid.

5 ive and safe in treating symptomatic uterine fibroids.

6 egulator REST in the pathogenesis of uterine fibroids.

7 -2)-8.10(-5)) with the risk and/or growth of fibroids.

8 pathway] is aberrantly expressed in uterine fibroids.

9 l for a gene that is misexpressed in uterine fibroids.

10 lar matrix deposition, a hallmark of uterine fibroids.

11 n several early-life factors and early-onset fibroids.

12 uterine fibroids and reduced the size of the fibroids.

13 urements to assess endometrial thickness and fibroids.

14 Of 956 eligible women, 251 (26.3%) had fibroids.

15 of the 2 collections and the risk of uterine fibroids.

16 at regular exercise might help women prevent fibroids.

17 fter focused ultrasound treatment of uterine fibroids.

18 ion may suggest possible pathways to prevent fibroids.

19 ence of myometrial perfusion defects and new fibroids.

20 might be useful in the treatment of uterine fibroids.

21 of the molecular basis of the common uterine fibroids.

22 -Mendelian manifestation of isolated uterine fibroids.

23 d elective abortion were not associated with fibroids.

24 ine artery embolization for the treatment of fibroids.

25 an women with no prior clinical diagnosis of fibroids.

26 2% of participants with serology results had fibroids.

27 ly larger fibroids than unexposed women with fibroids.

28 er's report), of whom 345 were found to have fibroids.

29 soy formula feeding and ultrasound-detected fibroids.

30 ing the molecular characteristics of uterine fibroids.

31 elied on self-report of clinically diagnosed fibroids.

32 modestly enlarged uterus with three uterine fibroids.

33 avy menstrual bleeding in women with uterine fibroids.

34 s and a visual lack of methylene blue in the fibroids.

35 rovides an excellent option to treat uterine fibroids.

36 lled, 6-month phase 3 trials (Elaris Uterine Fibroids 1 and 2 [UF-1 and UF-2]) to evaluate the effica

37 -up, 34% of 40 928 eligible participants had fibroids, 13% had endometriosis, and 7% had both.

38 participants without a history of diagnosed fibroids, 526 (20%) reported a new fibroid diagnosis dur

39 32% increase in the diameter of the largest fibroid (95% CI: 6%, 65%) and a 127% increase in total t

40 , and location but was stronger for multiple fibroids (adjusted risk ratio = 0.75, 95% confidence int

41 ge at menarche was inversely associated with fibroids (adjusted risk ratio = 0.87, 95% confidence int

42 roids." The most common somatic mutations in fibroids affect the Mediator complex subunit 12 (MED12;

43 Greater than 25% residual enhancement of a fibroid after embolization was considered an incomplete

44 Volume changes in treated fibroids after 6 months were compared with volume change

45 , sonohysterography depicted small submucous fibroids amenable to hysteroscopic myomectomy (n = 5), a

46 ife and childhood exposures with early-onset fibroids among black women and compared the results with

47 udy was to identify risk factors for uterine fibroids among women undergoing tubal sterilization.

48 mula feeding and ultrasound-detected uterine fibroids among young African-American women with no prio

49 A dominant submucosal fibroid and ischemia greater than or equal to 90% had gr

50 The volume of treated fibroid and nonperfused volume (NPV) were calculated wit

51 sociated with clinically significant uterine fibroids and aggressive renal tumors.

52 y relationships between drug distribution in fibroids and between vasculature characteristics, collag

53 tiologically implicated in diabetes, uterine fibroids and cancer.

54 zation, in women who had symptomatic uterine fibroids and did not want to undergo hysterectomy.

55 results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of ho

56 domly assigned 307 patients with symptomatic fibroids and excessive uterine bleeding to receive 3 mon

57 commonly performed procedure for symptomatic fibroids and has the lowest rate of reintervention (comp

58 en aged 40 years with a diagnosis of uterine fibroids and no desire for future pregnancy was followed

59 nalysis comparing representative sections of fibroids and normal myometrium showed a smaller number o

60 controlled excessive bleeding due to uterine fibroids and reduced the size of the fibroids.

61 ein, this article will discuss the nature of fibroids and their diagnosis, pharmacotherapy, surgical

62 n drug delivery for the treatment of uterine fibroids and tumors of similar composition.

63 e compared with volume changes in nontreated fibroids and with MR-based thermal dose estimates.

64 (mean age, 35.9 years +/- 4.8) with uterine fibroids and/or adenomyosis who were unable to conceive.

65 ong 5,512 participants, 10.4% had at least 1 fibroid, and 10.8% experienced a miscarriage.

66 egrees of volume reduction of the uterus and fibroid, and extents of symptom change.

67 the uterine fibroid, dominant (ie, largest) fibroid, and percentage of perfusion measurements from e

68 or age, BMI, race, family history of uterine fibroids, and isoflavone excretion, this trend remained

69 Parity, diabetes, fibroids, and poor social support were associated with p

70 a have suggested a possible association with fibroids, and serology for HSV-2 is much more sensitive

71 omatous polyps, five had hyperplasia, 11 had fibroids, and three had endometritis.

72 have >/= 2 tumors than unexposed women with fibroids (aPR 1.0, 95% CI: 0.7, 1.6).

73 Often, fibroids are asymptomatic and require no treatment.

74 Uterine fibroids are common tumors that can cause heavy menstrua

75 Uterine fibroids are hormonally responsive; estradiol and proges

76 Uterine fibroids are hormone-responsive neoplasms that are assoc

77 Uterine leiomyomas (fibroids) are a major source of gynecologic morbidity in

78 Uterine leiomyomata (fibroids) are common and clinically important tumors, bu

79 Uterine leiomyomata (fibroids) are hormonally responsive tumors, but little i

80 Uterine leiomyomata (fibroids) are the leading cause of hysterectomy in the U

81 Uterine leiomyomas (or fibroids) are the most common tumors in women of reprodu

82 Uterine leiomyomata, or fibroids, are benign tumors of the uterine myometrium th

83 Uterine leiomyomata (UL), also known as fibroids, are the most common pelvic tumors in women of

84 e acetate, 0.5 mg, once daily) in women with fibroid-associated bleeding.

85 pression of ovarian sex hormones, may reduce fibroid-associated bleeding.

86 e with incomplete infarction of the dominant fibroid at 3 years to determine extents of infarction, d

87 had intact uteri and no history of cancer or fibroids at enrollment in 1989.

88 ] years) with no prior clinical diagnosis of fibroids at enrollment were available for analysis.

89 Utilities for uterine fibroids before and after treatment were obtained with t

90 ate for the treatment of symptomatic uterine fibroids before surgery are uncertain.

91 ate for the treatment of symptomatic uterine fibroids before surgery are unclear.

92 Uterine leiomyomata (fibroids), benign neoplasms of the smooth muscle, are a

93 maging at higher magnification revealed that fibroid blood vessels were indeed perfused and stained w

94 Black women have a greater fibroid burden than whites, yet no study has systematica

95 d on self-report of a physician diagnosis of fibroids by the age of 30 years (n = 561).

96 ne collections (48 h apart) from 170 uterine fibroid cases and 173 controls were analyzed for isoflav

97 in cell cycle progression, was increased in fibroid cells and was significantly reduced by EGCG.

98 suggests that molecular characteristics of a fibroid changes with size.

99 ed the relationship between age at menarche, fibroid characteristics, and race.

100 sking patients about their family history of fibroids could encourage patient self-advocacy and infor

101 y mapped a gene that predisposes to multiple fibroids, cutaneous leiomyomata and renal cell carcinoma

102 Patients whose fibroids demonstrated an NPV of at least 20% also experi

103 f an association between age at menarche and fibroid development (regardless of characteristics), dem

104 rts a possible role of early-life factors in fibroid development.

105 been hypothesized to play a role in uterine fibroid development.

106 h White patients, there was a higher rate of fibroid diagnosis among Southeast Asian (IRR, 1.29; 95%

107 diagnosed fibroids, 526 (20%) reported a new fibroid diagnosis during follow-up.

108 and 84 206 patients (4.4%) received a first fibroid diagnosis during the study period.

109 5% CI, 1.34-1.39) also had elevated rates of fibroid diagnosis.

110 ies [3.9%]), the ovarian artery supplied the fibroids directly.

111 Two readers compared the uterine fibroid, dominant (ie, largest) fibroid, and percentage

112 state study that systematically screened for fibroids during very early pregnancy.

113 zation (mean score, 14; 95% CI: 11, 18), and fibroid embolization (mean score, 12; 95% CI: 9, 15) pat

114 ean score, 26; 95% CI: 22, 29; P < .001) and fibroid embolization (mean score, 24; 95% CI: 21, 27; P

115 antly different from those of women awaiting fibroid embolization (mean, 16; 95% CI: 14, 18; P = .23)

116 ation at aortography performed after uterine fibroid embolization (UFE) and, using OA arteriography a

117 rates after conventional and partial uterine fibroid embolization (UFE).

118 e five women who experienced menopause after fibroid embolization had bilateral ovarian artery-to-ute

119 zation patients, and 23 (95% CI: 18, 27) for fibroid embolization patients.

120 010, and December 27, 2010, prior to uterine fibroid embolization.

121 hemoembolization for cancer; and 60, uterine fibroid embolization.

122 n 76 consecutive patients undergoing uterine fibroid embolization.

123 diseases (polycystic ovary syndrome, uterine fibroids, endometriosis) as well as contraception.

124 be used in female healthcare: contraception, fibroids, endometriosis, and certain breast cancers.

125 Continued validation of uterine fibroids/endometriosis EHR studies is warranted to incre

126 patient and for the percentage of individual fibroid enhancement.

127 We randomly assigned women with symptomatic fibroids, excessive uterine bleeding (a score of >100 on

128 Some fibroids exhibited regions with partial methylene blue p

129 der, early-life risk factors for early-onset fibroids for black women were similar to those found for

130 ntaneous regression of fibroids occurs; (ii) fibroids from the same woman grow at different rates, de

131 ustrate the methodology by analyzing uterine fibroid gene expression data.

132 s that the molecular apparatus necessary for fibroid growth and development is established during tum

133 th rate; and (iv) age-related differences in fibroid growth between blacks and whites may contribute

134 Our analysis of the uterine fibroid growth gene expression data suggests that molecu

135 women less than 35 years of age had similar fibroid growth rates.

136 e ultrasound screening to detect and measure fibroids >/= 0.5 cm in diameter.

137 The majority of sampled fibroids had a strong negative correlation (Pearson's r=

138 Fibroids had an average elevated interstitial fluid pres

139 However, exposed women with fibroids had significantly larger fibroids than unexpose

140 mTOR) pathway in the pathogenesis of uterine fibroids has been suggested in several studies.

141 n physical activity and uterine leiomyomata (fibroids) has received little study, but exercise is pro

142 osis, polycystic ovary syndrome, and uterine fibroids-have remained stubbornly understudied despite t

143 erved in the nonsyndromic and common form of fibroids; however, loss of heterozygosity across FH appe

144 und between isoflavone excretion and uterine fibroids; however, the intake of soy foods, the primary

145 ment had a 37% lower risk of newly diagnosed fibroids (HR, 0.63; 95% CI, 0.38-1.05).

146 ne fibroid study, a cross-sectional study of fibroids in 1152 premenopausal women.

147 ometry performed during the treatments of 64 fibroids in 50 women (mean age, 46.6 years +/- 4.5 [stan

148 ter retrospective analysis of 71 symptomatic fibroids in 66 women was approved by the institutional r

149 icantly improves symptoms related to uterine fibroids in 85%-90% of patients.

150 e, can be associated with the common uterine fibroids in a syndrome called multiple cutaneous and ute

151 n, manifesting as skin leiomyoma and uterine fibroids in affected individuals.

152 y has systematically evaluated the growth of fibroids in blacks and whites.

153 indicators, were associated with early-onset fibroids in blacks.

154 tions for Ms P and symptomatic patients with fibroids in general is discussed.

155 can women enrolled in a prospective study of fibroid incidence and growth (recruited 2010-2012) in th

156 been shown in Eker rats to increase uterine fibroid incidence in adulthood.

157 s, the data suggest that although incomplete fibroid infarction may not affect outcome immediately, r

158 n the outcome analysis, the 12 with complete fibroid infarction were more likely not to have enhancin

159 ssue, the true barrier to transport in these fibroids is likely high interstitial fluid pressure, cor

160 Prior evidence attributing miscarriage to fibroids is potentially biased.

161 The growth of uterine fibroids is sex hormone-dependent and commonly associate

162 Standard treatment of symptomatic fibroids is surgical removal by myomectomy or hysterecto

163 ns that are implicated in the progression of fibroids, is significantly enriched only in small tumors

164 Uterine fibroids (leiomyomas) are a major women's health problem

165 Uterine fibroids (leiomyomas) are the most common tumors of the

166 Uterine fibroids (leiomyomas) have historically been viewed as i

167 ifying mechanism for pathogenesis of uterine fibroids mediated by H19 and identify a pathway for futu

168 n's Health Study were asked about history of fibroids, medical records were obtained, and vaginal ult

169 , a 41-year-old woman with recurrent uterine fibroids, menorrhagia, anemia, and fatigue who wishes to

170 Nor were exposed women with fibroids more likely to have >/= 2 tumors than unexposed

171 lready approved for the treatment of uterine fibroids, MRgFUS is in ongoing clinical trials for the t

172 een HSV-2 seropositivity and the presence of fibroids (multivariable-adjusted odds ratio = 0.94, 95%

173 th no laparoscopic evidence of or history of fibroids (n = 1,268).

174 ted an abnormal endometrial echo (n = 14) or fibroids (n = 14).

175 ed endometrial polyps (n = 9), intracavitary fibroids (n = 3), placental polyp (n = 1), and a normal

176 5-1987) or who reported a history of uterine fibroids (n = 317).

177 Four patients developed new fibroids, none of which has caused symptoms.

178 re any associations with size of the largest fibroid, number of fibroids, or total fibroid volume.

179 Uterine fibroids occur in approximately 50% of women over the ag

180 conclude that (i) spontaneous regression of fibroids occurs; (ii) fibroids from the same woman grow

181 ivity were significantly less likely to have fibroids (odds ratio = 0.6, 95% confidence interval = 0.

182 ually unchanged after adjustment for uterine fibroids or endometriosis history.

183 itions that lead to surgery, such as uterine fibroids or endometriosis.

184 Although uterine leiomyomata (also known as fibroids or myomas) affect the reproductive health and w

185 Uterine leiomyomas (fibroids or myomas), benign tumours of the human uterus,

186 isk was marginally related to having uterine fibroids (OR=0.6, 95% CI: 0.5, 1.0) and long-term versus

187 ences in breast fibrocystic disease, uterine fibroids, or endometrial lining thickness as assessed by

188 with size of the largest fibroid, number of fibroids, or total fibroid volume.

189 ked significantly in EC313-treated xenograft fibroids (p < 0.0001).

190 embolized, leaving the large vessels of the fibroids patent.

191 The incidence of fibroids peaks in the fifth decade of age and they are m

192 mal myometrium, and that the loss of REST in fibroids permits GPR10 expression.

193 stronger association for women with multiple fibroids, possibly reflecting a stronger association for

194 Fibroid presence, number, type, and volume were assessed

195 Endovaginal ultrasounds were conducted, and fibroid presence, number, type, volume, and diameter wer

196 esults were analyzed for the total number of fibroids present in the uterus of each patient and for t

197 association between soy formula feeding and fibroid prevalence [adjusted prevalence ratio (aPR) 0.9,

198 association between soy formula feeding and fibroid prevalence and tumor number using log-binomial r

199 d published estimates of ET distribution and fibroid prevalence, diagnostic test characteristics of t

200 ould not be attributed to reverse causation (fibroids preventing exercise).

201 nd in one patient during receipt of placebo (fibroid protruding through the cervix).

202 Seven percent of fibroids regressed (>20% shrinkage).

203 those who underwent myomectomy had a better fibroid-related quality of life at 2 years than those wh

204 The primary outcome was fibroid-related quality of life, as assessed by the scor

205 Clinical success for fibroid-related symptoms was 78.6% (282 of 359).

206 When data for women who reported major fibroid-related symptoms were excluded, results remained

207 f AP-1 loss on gene transcription in uterine fibroids remains poorly understood.

208 ntaining foods on the development of uterine fibroids remains to be determined.

209 ,850; 95% CI, -$31,629 to -$30,091), uterine fibroid resection (-$1509; 95% CI, -$1754 to -$1280), an

210 -37.7 days; 95% CI, -41.1 to -34.3), uterine fibroid resection (mean difference, -11.7 days; 95% CI,

211 of an IGF-I autocrine loop predicts uterine fibroid responsiveness to tamoxifen.

212 was to evaluate the relation between uterine fibroid risk and phytoestrogen exposure.

213 idence for an influence of HSV-2 exposure on fibroid risk in young African-American women.

214 evated diastolic blood pressure may increase fibroid risk through uterine smooth muscle injury, not u

215 rts have provided some support for increased fibroid risk with infant soy formula feeding in women, b

216 Racial disparities also impact fibroid risk.

217 ciation between lignan excretion and uterine fibroid risk.

218 nd blood biomarkers were not associated with fibroid risk.

219 ase in diastolic blood pressure, the risk of fibroids rose 8% (5-11%) and 10% (7-13%) among nonusers

220 T1-weighted contrast-enhancing fibroids selected for treatment had no hyperintense or h

221 The Study of Environment, Lifestyle & Fibroids (SELF) is an ongoing cohort study of 1,696 Afri

222 a from the Study of Environment, Lifestyle & Fibroids (SELF), a cohort of 1,693 African-American wome

223 Both pretreatment fibroid signal intensity (SI) and posttreatment NPV pred

224 l showed that EGCG was effective in reducing fibroid size and its associated symptoms; however, its m

225 Among those with fibroids, we compared fibroid size between soy formula-exposed and unexposed w

226 es, despite a uniform hormonal milieu; (iii) fibroid size does not predict growth rate; and (iv) age-

227 tive association in individual analyses with fibroid size, type, and location but was stronger for mu

228 We prospectively tracked growth for 262 fibroids (size range: 1-13 cm in diameter) from 72 preme

229 In the group with fibroids, sonohysterography depicted small submucous fib

230 ate associations between age at menarche and fibroid status and to test for interactions with race.

231 Fibroid status was based on ultrasound screening.

232 gnancy loss in a prospective cohort in which fibroid status was uniformly documented in early pregnan

233 se interval spanning FH in the NIEHS Uterine fibroid study, a cross-sectional study of fibroids in 11

234 ter-pair families from the Finding Genes for Fibroids study.

235 me-scale studies have revealed mutations and fibroid subtype-specific expression changes in key drive

236 r size of UFs, and the existence of multiple fibroid subtypes driven by key pathway genes regulated b

237 elated quality-of-life domain of the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionna

238 new polyps in these women and 13% had fewer fibroids than in controls.

239 women fed soy formula as infants have larger fibroids than unexposed women provides further support f

240 women with fibroids had significantly larger fibroids than unexposed women with fibroids.

241 hinese participants were more likely to have fibroids than White participants (Black or African Ameri

242 used region extended to locations within the fibroid that clearly were not heated.

243 Uterine fibroids, the most common type of tumor among women of r

244 que feature that led to naming these tumors "fibroids." The most common somatic mutations in fibroids

245 his study intended to review HIFU in uterine fibroid therapy, to evaluate the role of HIFU in the the

246 h participants without a maternal history of fibroids, those reporting maternal history had an adjust

247 Among women with symptomatic uterine fibroids, those who underwent myomectomy had a better fi

248 ) differed from posttreatment ADC values for fibroid tissue (1078 mm(-6)/sec2 +/- 293) (P = .001).

249 Posttreatment ADC values for nontreated fibroid tissue (1685 mm(-6)/sec2 +/- 468) differed from

250 6) and nontreated (1437 mm(-6)/sec2 +/- 270) fibroid tissue at 6-month follow-up was observed.

251 outcome immediately, regrowth of uninfarcted fibroid tissue may result in symptom recurrence.

252 lene blue was able to passively diffuse into fibroid tissue, the true barrier to transport in these f

253 gen content and solid stress observed in the fibroid tissue.

254 myometrium and relatively little within the fibroid tissues.

255 s, nonperfused areas could extend within the fibroid to unheated areas.

256 We sought to determine the relationship of fibroids to pregnancy loss in a prospective cohort in wh

257 hese findings imply that surgical removal of fibroids to reduce risk of miscarriage deserves careful

258 Uterine fibroid treatment using HIFU was effective and safe in t

259 Surgery has been the mainstay of fibroid treatment, and various minimally invasive proced

260 Quality of life increased after all fibroid treatments.

261 le in activating stem cell proliferation and fibroid tumor development.

262 essential for uterine leiomyoma (LM, a.k.a., fibroid) tumorigenesis, but the underlying cellular and

263 The uterus frequently develops benign fibroid tumors but uterine cancers are relatively rare.

264 ly (ORs = 1.06-2.09) associated with uterine fibroids (UF), PCOS, heavy menstrual bleeding (HMB), and

265 Uterine fibroids (UFs) are associated with irregular or excessiv

266 Uterine leiomyomas or fibroids (UFs) are benign tumors characterized by hyperp

267 were aged 23-34 years and were screened for fibroids using a standardized ultrasound examination at

268 r occult tumors in common conditions such as fibroids, validation of our data in family-based studies

269 leeding (PBAC score of <75) and reduction of fibroid volume at week 13, after which patients could un

270 On average, the fibroid volume reduction at 6 months increased as the ab

271 Fibroid volume was measured by computerized analysis of

272 The median changes in total fibroid volume were -21%, -12%, and +3% (P=0.002 for the

273 comfort, anemia, and uterine volume, but not fibroid volume.

274 argest fibroid, number of fibroids, or total fibroid volume.

275 Mean baseline ADC value in fibroids was 1504 mm(-6)/sec2 +/- 290.

276 Baseline volume of treated fibroids was 255.5 cm(3) +/- 201.7 (standard deviation),

277 Presence of fibroids was associated with miscarriage in models witho

278 No characteristic of fibroids was associated with risk.

279 Enhancement of individual fibroids was measured with quartile intervals.

280 fused portions of the incompletely infarcted fibroids was seen in three patients, two of whom had rec

281 Among those with fibroids, we compared fibroid size between soy formula-e

282 and the linked genes in nonsyndromic uterine fibroids, we explored a two-megabase interval spanning F

283 Early-onset fibroids were assessed based on self-report of a physici

284 Fibroids were classified as hyperintense or hypointense

285 UFE, only the small arterial vessels to the fibroids were embolized, leaving the large vessels of th

286 mprised women aged 17-44 years whose uterine fibroids were first visualized at the time of tubal ster

287 rs most strongly associated with early-onset fibroids were in utero diethylstilbestrol (DES; RR = 2.0

288 cant differences in endometrial thickness or fibroids were observed between the groups.

289 Uterine fibroids were used as a perfusion model.

290 Adult patients with a diagnosis of uterine fibroids who underwent hysterectomy, myomectomy, or UFE

291 outpatient procedures for women with uterine fibroids who want to conceive.

292 lly cycling premenopausal women with uterine fibroids, who were not on hormonal treatment at the time

293 teroscopic myomectomy (n = 5), a small mural fibroid with a normal cavity, which obviated surgical in

294 arger decrease in SSS than did patients with fibroids with an NPV less than 20% (50.1% +/- 19.8 vs 32

295 13.0 and 17.2% +/- 20.1, respectively) than fibroids with an NPV less than 20% or with high SI (10.7

296 ted 12-month volume reduction independently: Fibroids with an NPV of at least 20% or with low SI both

297 The trend for a reduced risk of uterine fibroids with increasing quartiles of lignan excretion w

298 Fibroids with low SI on pretreatment T2-weighted MR imag

299 determine both the size and location of the fibroids within the uterus.

300 esulted in a dose-dependent reduction in the fibroid xenograft weight (p < 0.01).